TVRD
Tvardi Therapeutics, Inc.
1W: -5.4%
1M: -19.7%
3M: -26.6%
YTD: -22.1%
$3.02
+0.02 (+0.67%)
After Hours: $3.05 (+0.03, +0.99%)
Weekly Expected Move ±8.5%
$3
$3
$3
$3
$4
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Watch
25
Insider—
Congress—
ETF Holdings—
Key Statistics
Market Cap$28.3M
52W Range2.81-43.65
Volume63,307
Avg Volume63,200
Beta0.13
Dividend—
Analyst Ratings
Company Info
CEOImran Alibhai
Employees17
SectorHealthcare
IndustryBiotechnology
IPO Date2025-04-16
2450 Holcombe Blvd, Suite X
Sugar Land, TX 77021
US
Sugar Land, TX 77021
US
832-413-1362
About Tvardi Therapeutics, Inc.
Tvardi Therapeutics is a clinical-stage biopharmaceutical company focused on developing novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases with significant unmet need. Their lead candidate, TTI-101, is currently in Phase 2 clinical trials for idiopathic pulmonary fibrosis (IPF) and hepatocellular carcinoma (HCC).
Latest News
Tvardi Therapeutics to Participate in the Raymond James Biotech Innovation Symposium
Tvardi Therapeutics GAAP EPS of -$0.78 misses by $0.19
Tvardi Therapeutics Announces Fourth Quarter and Full-Year 2025 Results and Provides Business Update
Tvardi Therapeutics Announces Fourth Quarter and Full-Year 2025 Results and Provides Business Update
Tvardi Therapeutics, Inc. (NASDAQ:TVRD) Receives $55.50 Consensus Price Target from Analysts
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| O'Brien Stephen Paul | A-Award | 15,000 | $3.90 | 2026-01-29 |
| Conn Avi Daniel | A-Award | 45,000 | $3.90 | 2026-01-29 |
| Kauh John Saewook M. | A-Award | 45,000 | $3.90 | 2026-01-29 |
| Alibhai Imran Nizamu | A-Award | 115,000 | $3.90 | 2026-01-29 |
| O'Brien Stephen Paul | A-Award | 4,000 | $4.20 | 2025-12-16 |